Medichem, S.A.

medichem.es

Meet an independently-owned developer and manufacturer of Finished Dosage Forms (FDF) , Active Pharmaceutical Ingredients (API) and HPAPI. From its headquarters in Barcelona, Spain, Medichem has grown into one of the largest worldwide manufacturers of Generics and Chlorhexidine in the pharmaceutical industry. Made up of a workforce of 450 talented individuals located in Spain (HQ), the USA, Malta and China, Medichem serves 60 countries worldwide.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AI

BENCHLING REINFORCES SECURITY COMMITMENT WITH TYPE 2 SOC 2

Benchling | January 27, 2023

news image

On January 27, 2023, Benchling, the R&D cloud that powers the biotechnology sector, announced that it has passed the System and Organization Controls (SOC) 2 certification. Schellman, an independent Certified Public Accounting (CPA) firm, conducted the Type 2 SOC 2 test according to the AICPA's SOC 2 standards. Type 2 SOC 2 evaluates the design and operational performance of an organization's security processes and controls to meet its security goals and customer com...

Read More

Medical, Diagnostics

PREMIER RESEARCH AND INSILICOTRIALS PARTNER FOR RARE DISEASE THERAPY DEVELOPMENT

Premier Research | March 14, 2023

news image

Premier Research has partnered with InSilicoTrials, a leader in using artificial intelligence (AI) and computational modeling and simulation (CM&S) to speed up the development of new therapies and medical devices. Premier Research helps biotech and device companies take their ideas from the idea stage to the commercialization stage. The aim of the partnership is to make it easier, faster, and safer for treatments for rare diseases to get approval from the government. CM&...

Read More

Industrial Impact

AMNIO TECHNOLOGY LAUNCHES TWO NEW DUAL-LAYER ALLOGRAFTS, FDA RECOGNIZES PRODUCTS AS MINIMALLY MANIPULATED, HOMOLOGOUS USE HCT/PS

Amnio Technology | February 15, 2022

news image

Amnio Technology, a global leader in the development of and distribution of amniotic tissue allografts is announcing the launch of two new PalinGen® membrane products, PalinGen® Dual-Layer Membrane and Dual Layer PalinGen® X-Membrane. The new allografts, like the entire family of PalinGen® membrane products, are minimally manipulated, homologous use and chorion-free. The dual-layered nature of the allografts allow for unidirectional application with two outward facing epithelial ...

Read More

Medical, Diagnostics

ASTELLAS AND POSEIDA THERAPEUTICS ANNOUNCE STRATEGIC INVESTMENT TO SUPPORT POSEIDA'S COMMITMENT TO REDEFINING CANCER CELL THERAPY

PRNewswire | August 08, 2023

news image

Astellas Pharma Inc. and Poseida Therapeutics, Inc. announced a strategic investment to support the advancement of Poseida's commitment to redefining cancer cell therapy. Under the terms of the transaction agreements, Astellas will invest a total of $50 million, including $25 million to acquire 8,333,333 shares of common stock of Poseida (approximately 8.8% of the outstanding common stock of Poseida) at $3.00 per share in a private placement and a one-time $25 million paymen...

Read More
news image

AI

BENCHLING REINFORCES SECURITY COMMITMENT WITH TYPE 2 SOC 2

Benchling | January 27, 2023

On January 27, 2023, Benchling, the R&D cloud that powers the biotechnology sector, announced that it has passed the System and Organization Controls (SOC) 2 certification. Schellman, an independent Certified Public Accounting (CPA) firm, conducted the Type 2 SOC 2 test according to the AICPA's SOC 2 standards. Type 2 SOC 2 evaluates the design and operational performance of an organization's security processes and controls to meet its security goals and customer com...

Read More
news image

Medical, Diagnostics

PREMIER RESEARCH AND INSILICOTRIALS PARTNER FOR RARE DISEASE THERAPY DEVELOPMENT

Premier Research | March 14, 2023

Premier Research has partnered with InSilicoTrials, a leader in using artificial intelligence (AI) and computational modeling and simulation (CM&S) to speed up the development of new therapies and medical devices. Premier Research helps biotech and device companies take their ideas from the idea stage to the commercialization stage. The aim of the partnership is to make it easier, faster, and safer for treatments for rare diseases to get approval from the government. CM&...

Read More
news image

Industrial Impact

AMNIO TECHNOLOGY LAUNCHES TWO NEW DUAL-LAYER ALLOGRAFTS, FDA RECOGNIZES PRODUCTS AS MINIMALLY MANIPULATED, HOMOLOGOUS USE HCT/PS

Amnio Technology | February 15, 2022

Amnio Technology, a global leader in the development of and distribution of amniotic tissue allografts is announcing the launch of two new PalinGen® membrane products, PalinGen® Dual-Layer Membrane and Dual Layer PalinGen® X-Membrane. The new allografts, like the entire family of PalinGen® membrane products, are minimally manipulated, homologous use and chorion-free. The dual-layered nature of the allografts allow for unidirectional application with two outward facing epithelial ...

Read More
news image

Medical, Diagnostics

ASTELLAS AND POSEIDA THERAPEUTICS ANNOUNCE STRATEGIC INVESTMENT TO SUPPORT POSEIDA'S COMMITMENT TO REDEFINING CANCER CELL THERAPY

PRNewswire | August 08, 2023

Astellas Pharma Inc. and Poseida Therapeutics, Inc. announced a strategic investment to support the advancement of Poseida's commitment to redefining cancer cell therapy. Under the terms of the transaction agreements, Astellas will invest a total of $50 million, including $25 million to acquire 8,333,333 shares of common stock of Poseida (approximately 8.8% of the outstanding common stock of Poseida) at $3.00 per share in a private placement and a one-time $25 million paymen...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us